AMG 853 / Amgen - LARVOL DELTA

AMG853, A Bispecific Prostaglandin D Receptor 1 and 2 Antagonist, Dampens Basophil Activation and Related Lupus-Like Nephritis Activity in Lyn-Deficient Mice. (PubMed, Front Immunol) - "Ten days of treatment with AMG853 was consequently sufficient in reducing the dsDNA-specific IgG titers, circulating immune complex glomerular deposition, and renal inflammation, which are hallmarks of lupus-like disease. Thus, bispecific PTGDR-1 and PTGDR-2 antagonists, such as AMG853, are a promising class of drugs for the treatment or prevention of organ damage in systemic lupus erythematosus."

Journal • Preclinical • Glomerulonephritis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Nephrology • Systemic Lupus Erythematosus • PTGDR

[VIRTUAL] Increased L-PGDS and PGD2 in the spinal cord contribute to mechanical allodynia via DP2 receptor in a rat model of cisplatin-induced peripheral neuropathy (IASP 2021) - "To evaluate their role in mechanical allodynia, AT 56, MK 0524, AMG 853, or CAY 10471, an L-PGD synthase inhibitor, DP1, DP 1/2, or DP2 receptor antagonist, respectively, was intrathecally administered 10 min prior to the von Frey test. The amount of L- but not H-PGD synthase was increased in the spinal cord in CIPN compared to control animals. These data suggest that increased L-PGD synthase in response to cisplatin administration and a consequent PGD2 signaling via DP2 signaling pathway in the spinal cord may contribute to the mechanical allodynia exhibited in CIPN. An agent interfering DP2 receptor activation or its downstream pathway may be utilized as a tool for managing CIPN."

Preclinical • Pain

Prostaglandin D contributes to cisplatin-induced neuropathic pain in rats via DP2 receptor in the spinal cord. (PubMed, Korean J Pain) - "The DP1 and DP2 antagonist AMG 853 and the selective DP2 antagonist CAY10471, but not the DP1 antagonist MK0524, significantly increased the paw withdrawal threshold compared to vehicle controls (P = 0.004 and P < 0.001, respectively). In the CIPN group the protein expression level of L-PGDS, but not of H-PGDS, was significantly increased compared to the control group (P < 0.001). The findings presented here indicate that enhanced PGD signaling, via upregulation of L-PGDS in the spinal cord, contributes to mechanical allodynia via DP2 receptors in a cisplatin-induced neuropathic pain model in rats, and that a blockade of DP2 receptor activation may present a novel therapeutic target for managing CIPN."

Journal • Immunology • Inflammation • Neuralgia • Oncology • Pain • Peripheral Neuropathic Pain

Credit Suisse Annual Healthcare Conference. (Amgen) -

AMG853 / Amgen; P2 for asthma;

Efficacy and safety of AMG 853 in asthma: Results of a phase 2, randomized, double-blind, placebo-controlled study (AAAAI 2012) - Presentation time: Mar 5 2012; P2, N=352; Although AMG 853 demonstrated no associated risks for subjects, no significant improvements in both Asthma Control Questionnaire (ACQ) scores & prebronchodilator FEV1 from baseline to week 12 were observed vs. PBO

P2 data • Immunology